Construction of novel tumor necrosis factor-alpha mutants with reduced toxicity and higher cytotoxicity on human tumor cells

Sci China C Life Sci. 2003 Feb;46(1):1-9. doi: 10.1007/BF03182679.

Abstract

Two tumor necrosis factor-alpha mutants MT1 (32Trp157Phe) and MT2 (2Lys30Ser-32Trp 157Phe) were constructed by site-directed mutagenesis. These mutants were soluble and over-expressed inE. coli. The purity of purified mutants was above 95% by serial chromatography. The results of Western blot indicated that these mutants could be cross-reactive with monoclonal antibody against native hTNF-alpha. Compared to parent hTNF-alpha, the cytotoxicity of these mutants on murine fibrosarcoma L929 cell lines reduced 4-5 orders of magnitude but was equivalent to that of native hTNF-alpha on human tumor cell lines. The LD50 of mutant MT1 was reduced to 0.34% of wild type and the dose of MT2 that resulted in 30% death of mice reduced to less than 1/700 that of parent hTNF-alpha.

MeSH terms

  • Amino Acid Substitution
  • Animals
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / toxicity
  • Base Sequence
  • Cell Line, Tumor
  • DNA Primers / genetics
  • Escherichia coli / genetics
  • Female
  • Humans
  • Lethal Dose 50
  • Male
  • Mice
  • Mutagenesis, Site-Directed
  • Protein Engineering
  • Receptors, Tumor Necrosis Factor / drug effects
  • Recombinant Proteins / genetics
  • Recombinant Proteins / pharmacology
  • Recombinant Proteins / toxicity
  • Tumor Necrosis Factor-alpha / genetics*
  • Tumor Necrosis Factor-alpha / pharmacology
  • Tumor Necrosis Factor-alpha / toxicity*

Substances

  • Antineoplastic Agents
  • DNA Primers
  • Receptors, Tumor Necrosis Factor
  • Recombinant Proteins
  • Tumor Necrosis Factor-alpha